On 5 November 2020, Beximco Pharmaceuticals Limited provided the following update in relation to the Memorandum of Understanding, signed in November 2020, for the supply and distribution of 30 million doses of the Oxford University/AstraZeneca SARS-CoV-2 vaccine, AZD1222, in Bangladesh, the status of regulatory approvals required and the Company's plans to purchase and distribute the Vaccine to the private healthcare market in Bangladesh. In its announcement on 5 November 2020, the Company outlined the terms of the MOU, signed with the Serum Institute of India Pvt. Ltd. and the Government of Bangladesh. A formal purchase agreement, in the same terms as the MOU, was subsequently entered into by the parties in December 2020. The Agreement was subject to the Vaccine receiving either (i) "Emergency Use Listing" by the World Health Organisation, or (ii) "Emergency Use Authorisation" by the UK's Medicines & Healthcare products Regulatory Agency (MHRA) or the US Food and Drug Administration (USFDA), as well as permission from the Bangladesh Director General of Drug Administration's for import into the country. As announced by the GOB, the Vaccine was approved by DGDA for emergency use in Bangladesh on 7 January 2021. All doses of the Vaccine being purchased by the GOB for its mass vaccination programme are contracted to be supplied within six months of approval. The first doses are expected to arrive in Bangladesh towards the end of January 2021, with further deliveries taking place on a monthly basis thereafter until June 2021. Under the Agreement, Beximco Pharma is acting as the exclusive distributor for the Vaccine in Bangladesh.